New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
16:44 EDTAGRXAgile Therapeutics reports allowance of additional patent claims for Skinfusion
Agile Therapeutics announced that the U.S. Patent and Trademark Office issued a Notice of Allowance on July 17 for additional patent claims covering dosing regimens using the company's lead product candidate Twirla, currently in Phase 3 development. The allowed patent, which is published as US Patent Application 20140072615, is based on Agile's prior patent, US 7,384,650, covering the formulation for Twirla. Agile will submit information regarding this patent to the FDA for inclusion in the FDA's Orange Book if the company's New Drug Application for Twirla is approved. The company has multiple additional patents and applications on file, all relating to further advances in Skinfusion transdermal delivery system.
News For AGRX From The Last 14 Days
Check below for free stories on AGRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
16:44 EDTAGRXAgile Therapeutics reports allowance of additional patent claims for Skinfusion
Agile Therapeutics announced that the U.S. Patent and Trademark Office issued a Notice of Allowance on July 17 for additional patent claims covering dosing regimens using the company's lead product candidate Twirla, currently in Phase 3 development. The allowed patent, which is published as US Patent Application 20140072615, is based on Agile's prior patent, US 7,384,650, covering the formulation for Twirla. Agile will submit information regarding this patent to the FDA for inclusion in the FDA's Orange Book if the company's New Drug Application for Twirla is approved. The company has multiple additional patents and applications on file, all relating to further advances in Skinfusion transdermal delivery system.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use